EPCAM Genotype

If colon or uterine cancer runs in your family, especially in relatives diagnosed young, this test can reveal one inherited cause that standard mismatch-repair gene sequencing can miss. A specific kind of deletion in this gene quietly disables a nearby DNA-repair gene and drives Lynch syndrome, the most common inherited form of colorectal cancer.

Knowing you carry that deletion changes how early and how often you should be screened, sometimes decades before a tumor would ever appear. It also tells your siblings, children, and parents whether they should be tested.

What This Gene Actually Does

EPCAM (epithelial cell adhesion molecule) is a gene that makes a protein sitting on the surface of the cells lining your organs, where it helps neighboring cells hold together and pass signals. Think of it as a cell-surface glue-and-signal protein made by the lining tissues of the gut, glands, and other epithelial organs, rather than something that circulates in your blood at a measurable level.

This test does not measure the protein. It reads the DNA sequence at this gene to look for inherited changes, and the change that matters most clinically is a deletion at the very end of the gene, its 3' end, including the last exons and the signal that normally tells the cell where to stop reading.

How a Deletion Triggers Lynch Syndrome

Immediately downstream of this gene sits MSH2, one of a small set of genes your cells use to proofread and fix mistakes when DNA copies itself (the mismatch-repair genes). When the tail end of the EPCAM gene is deleted along with its normal stop signal, the machinery reading it does not stop where it should. It runs onward and chemically silences the MSH2 gene in the tissues where EPCAM is active, mainly the lining of the gut and uterus.

The result is Lynch syndrome: cells in those linings lose their DNA proofreading and accumulate errors that can turn into cancer. These end-of-gene deletions are a recurrent, well-documented cause of Lynch syndrome and account for at least 1 to 3 percent of families where the condition has been explained by a genetic cause. Only these large deletions of the gene's tail cause Lynch syndrome; other, rarer changes that simply knock out the gene are instead linked to a separate inherited intestinal condition called congenital tufting enteropathy, not to cancer risk, which is why the exact type of change matters for genetic counseling. Because MSH2 itself stays physically intact, standard sequencing of the mismatch-repair genes can come back normal even though the person clearly has the syndrome, which is exactly why looking at this gene matters.

Colon Cancer Risk

Colon cancer is the strongest and most consistent risk tied to these deletions. In a cohort of deletion carriers, 93 of 194 developed colorectal cancer, the average first diagnosis came at age 43, and the cumulative risk reached about 75 percent by age 70.

In that cohort the colon cancer risk looked comparable to people who carry classic MSH2 or MLH1 mutations, the other well-known Lynch syndrome genes. That comparison deserves caution: the EPCAM estimates come from a small number of older studies that may overstate risk, and more recent data put MSH2 colorectal cancer risk somewhat lower. Even so, the practical takeaway is concrete: if you carry one of these deletions, colonoscopy should start early and repeat frequently, because tumors here tend to arise young and can be caught or prevented when surveillance is aggressive.

Uterine Cancer Risk

For women, the risk of uterine (endometrial) cancer is real but generally lower than the colon risk, with estimates ranging from about 12 percent up to roughly 25 percent by age 70. That is meaningfully less than what MSH2 mutation carriers face, and the higher-risk cases cluster in a specific situation: when the deletion is large enough to reach into the neighboring MSH2 control region.

This looks like a contradiction at first. The deletion silences MSH2, so why would uterine risk be lower than in people whose MSH2 gene is directly mutated? The answer is that this is not a simple good-number, bad-number marker. The silencing is tissue-restricted, switching MSH2 off only in cells that normally make the EPCAM protein. That preserves the classic colon risk but softens the uterine risk, unless the deletion physically extends into MSH2's own switch, in which case the uterine risk climbs back up. The exact size and boundaries of your deletion, not just its presence, shape your personal risk.

Stomach and Small-Intestine Cancer

Lynch syndrome carriers, including those with these deletions, also have a modestly raised lifetime risk of stomach and duodenal (upper small-intestine) cancer. This risk stays very low before age 50 and rises later, so it shapes long-term monitoring rather than screening in your 30s. In large registries, stomach cancer has been tied more strongly to the MLH1 and MSH2 genes than to EPCAM deletions, though EPCAM-specific data are sparse, so this reflects limited evidence rather than a definitive head-to-head comparison.

A Research Note on Common Spelling Variants

Separate from the deletions, researchers have studied common single-letter spelling changes in this gene, most often a variant called rs1126497 that swaps one amino acid in the protein. This is exploratory, early-stage science with no standardized clinical cutoffs, and the findings come mostly from single studies in Chinese populations. Treat anything below as interesting context, not a basis for decisions.

In a breast cancer study of 1,643 cases and 1,818 controls, carrying this variant was linked to roughly 40 percent higher odds of breast cancer and to earlier onset. In non-small-cell lung cancer, carriers were about 40 percent more likely to die and about 34 percent more likely to have their cancer come back. In liver cancer treated with a specific catheter-based therapy, the variant did not predict survival overall, but among the subgroup whose tumor had invaded a major liver vein, carriers had about 70 percent higher risk of dying. These signals are cohort-specific and have not been broadly confirmed, so they do not yet change how anyone is screened or treated.

A One-Time Result You Act On for Years

Your genotype does not change. This is a once-in-a-lifetime test, and a clear result does not need to be repeated unless a confirmatory method is warranted to verify an unexpected finding. The value is not in retesting the gene; it is in integrating the result into decades of screening decisions.

What does need ongoing tracking is the downstream cancer risk. If you carry a deletion, the payoff is a lifetime surveillance plan: early and frequent colonoscopy, and for women, discussion of uterine monitoring or risk-reducing options. Think of the genotype as the fixed fact and your colonoscopy schedule as the moving part you actually watch over time.

What an Abnormal Result Should Prompt

A positive result is a starting point for a coordinated workup, not an endpoint. The right next steps depend on your situation and are best mapped with a genetics professional.

• Confirm the finding: if the deletion was detected by a chip-based or screening method, a second technique such as MLPA (a lab method built to detect missing or extra pieces of DNA) or targeted sequencing can verify it before it drives major decisions.
• Test the tumor if cancer is present: staining the tumor tissue for the mismatch-repair proteins (immunohistochemistry, or IHC) and checking for microsatellite instability (a fingerprint of failed DNA proofreading) confirms that the deletion is actually silencing MSH2 in that cancer.
• Involve a genetic counselor or specialist: a counselor or a gastroenterologist familiar with hereditary cancer can translate deletion size and family history into a concrete surveillance plan and interval.
• Talk to your relatives: because this is inherited, first-degree relatives (parents, siblings, children) each have a meaningful chance of carrying the same deletion, and cascade testing lets carriers start early screening while clearing non-carriers from unnecessary procedures.

When Results Can Be Misleading

Unlike blood levels, a genotype does not drift with your day or your diet. The pitfalls here are about coverage and interpretation, not physiology.

• Panel coverage: this test detects only the variants it is designed to find. A negative result does not rule out a mutation in MSH2 or the other Lynch syndrome genes, so a clean EPCAM result with a strong family history still warrants broader mismatch-repair gene testing.
• Ancestry and variant frequency: the clinical meaning of a rare change can differ by ancestral background, and populations outside Europe and North America are underrepresented in the data, which raises the chance of an uncertain result.
• Variants of uncertain significance: a spelling change may be reported whose effect is genuinely unknown. Current guidelines say such uncertain variants should not drive treatment or surveillance decisions, and many are later reclassified as harmless as evidence accumulates.
• Germline versus tumor DNA: this test assumes it is reading the DNA you were born with. A sample contaminated by tumor tissue can produce a misleading call, which is one more reason unexpected results are worth confirming.